ArticlePlatelets2022
Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength.
Article in Platelets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis.Journal of thrombosis and haemostasis : JTH · 2026Article
- HDL in Abdominal Aortic Aneurysm: Mechanistic Insight and Therapeutic Potential.Current atherosclerosis reports · 2026Review
- Beyond High-density Lipoprotein-cholesterol: Unraveling the Complexity of High-density Lipoprotein Functionality.Journal of atherosclerosis and thrombosis · 2025Review
- Apolipoprotein-A1 transports and regulates MMP2 in the blood.Nature communications · 2025Article
- Significance of APOB/APOA1 Ratio in the Prediction of Calcific Aortic Valve Disease.Cardiovascular therapeutics · 2025Article
- Visceral Adipose Tissue Inflammation and Vascular Complications in a Rat Model with Severe Dyslipidemia: Sex Differences and PAI-1 Tissue Involvement.Biomolecules · 2024Article
- Identification of oxylipins and lipid mediators in pulmonary embolism.Lipids in health and disease · 2024Article
- Proteomic Characterization of Plasma in Lemierre's Syndrome.Thrombosis and haemostasis · 2024Article
- Clot or Not? Reviewing the Reciprocal Regulation Between Lipids and Blood Clotting.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms.The Journal of clinical investigation · 2024Article
- Efficacy and safety of Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke with large vessel occlusion: a subgroup analysis of GIANT.Frontiers in pharmacology · 2024Article
- A novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer.Frontiers in immunology · 2024Article
- Why platelet mechanotransduction matters for hemostasis and thrombosis.Journal of thrombosis and haemostasis : JTH · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Apolipoprotein A-I (ApoA-I) is elevated in the plasma of a subgroup of trauma patients with systemic hyperfibrinolysis. We hypothesize that apoA-I inhibits platelet activation and clot formation. The effects of apoA-I on human platelet activation and clot formation were assessed by whole blood thrombelastography (TEG), platelet aggregometry, P-selectin surface expression, microfluidic adhesion, and Akt phosphorylation. Mouse models of carotid artery thrombosis and pulmonary embolism were used to assess the effects of apoA-I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.